86971-83-7

Basic information

• Product Name: methyl 5,6--dihydro-4H-pyran-3-carboxylate
• Synonyms: methyl 5,6--dihydro-4H-pyran-3-carboxylate;Methyl 3,4-Dihydro-2H-pyran-5-carboxylate
• CAS NO: 86971-83-7
• Molecular Formula: C7H10O3
• Molecular Weight: 142.1525
• Mol File: 86971-83-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 196.6±29.0 °C(Predicted)
• Appearance: /
• Density: 1.124±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: methyl 5,6--dihydro-4H-pyran-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5,6--dihydro-4H-pyran-3-carboxylate(86971-83-7)
• EPA Substance Registry System: methyl 5,6--dihydro-4H-pyran-3-carboxylate(86971-83-7)

Safety Data

• Hazardous Substances Data: 86971-83-7(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of the American Chemical Society, 105, p. 6755, 1983 DOI: 10.1021/ja00360a056

Upstream product

• 40915-37-5 5,6-dihydro-4H-pyran-3-carboxylic acid 
• 77-78-1 dimethyl sulfate 
• 110-87-2 3,4-dihydro-2H-pyran 
• 67-56-1 methanol 
• 79-37-8 oxalyl dichloride 
• 26274-19-1 5-bromo-3,4-dihydro-2H-pyran 
• 201230-82-2 carbon monoxide 
• 83124-87-2 5-(trichloroacetyl)-3,4-dihydro-2H-pyran 
• 109-88-6 magnesium methanolate 
• 98198-84-6 3,4-dihydro-2H-pyran-5-carbonyl chloride 
• 83124-70-3 2-Chlor-3-trichloracetyl-tetrahydro-4H-pyran 

Downstream Products

• 40915-37-5 5,6-dihydro-4H-pyran-3-carboxylic acid 

Relevant articles and documents

Synthesis and neuroprotective action of xyloketal derivatives in Parkinson's disease models

Parkinson's disease (PD) is the second most common neurodegenerative disease affecting people over age 55. Oxidative stress actively participates in the dopaminergic (DA) neuron degeneration of PD. Xyloketals are a series of natural compounds from marine mangrove fungus strain No. 2508 that have been reported to protect against neurotoxicity through their antioxidant properties. However, their protection versus 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity is only modest, and appropriate structural modifications are necessary to discover better candidates for treating PD. In this work, we designed and synthesized 39 novel xyloketal derivatives (1-39) in addition to the previously reported compound, xyloketal B. The neuroprotective activities of all 40 compounds were evaluated in vivo via respiratory burst assays and longevity-extending assays. During the zebrafish respiratory burst assay, compounds 1, 9, 23, 24, 36 and 39 strongly attenuated reactive oxygen species (ROS) generation at 50 μM. In the Caenorhabditis elegans longevity-extending assay, compounds 1, 8, 15, 16 and 36 significantly extended the survival rates (p +). In the MPP+-induced C57BL/6 mouse PD model, 40 mg/kg of 1 and 8 protected against MPP+-induced dopaminergic neurodegeneration and increased the number of DA neurons from 53% for the MPP+ group to 78% and 74%, respectively (p 0.001 vs. MPP+ group). Thus, these derivatives are novel candidates for the treatment of PD.

A New Indirect Application of Aggregative Activation: Synthesis of Esters by Cobalt-Catalyzed Carbonylation of Aryl, Heterocyclic, and Vinyl Halides under Atmospheric Pressure

Sun lamp illuminated alkoxycarbonylation of aryl, heteroaryl, and vinyl halides was performed under atmospheric pressure of CO in the presence of a cobalt catalyst in situ generated from Co(OAc)2.Illunination through a Pyrex flask was sufficient to catalyze the reaction.This process avoids the use of Co2(CO)8 and excess CH3I, which were required in the earlier procedure.A SRN1 mechanism is proposed.

A total synthesis of plumericin, allamcin, and allamandin. 2. A biomimetic strategy

-